My first reaction was in agreement with the majority of prior posts in supposing that it's likely harmless, and presents negligible damage. However, this is really a question of risk to benefit - as no studies have been conducted on this particular interaction. We can inform this question with some extrapolation from the activities observed from other serotonergic drugs during pregnancy, and though the interactions certainly wont be identical, they are certainly relevant.
Here is a study named Effects of Exposure to Selective Serotonin Reuptake Inhibitors During Pregnancy on Serotonergic Symptoms in Newborns and Cord Blood Monoamine and Prolactin Concentrations, in which I was fortunate to come upon some potentially relevant statements; if interested, allow me to direct your attention to a few of the more salient ones:
Originally Posted by Kari Laine, MD, PhD; Tuija Heikkinen, MD; Ulla Ekblad, MD, PhD; Pentti Kero, MD, PhD
The exposure to SSRI treatment during pregnancy ranged from 7 to 41 weeks. In the SSRI group, 9 women were exposed to citalopram and 6 women to fluoxetine already during the first trimester of pregnancy. No malformations were detected. The duration of pregnancy was similar in the SSRI group and the control group.
There were no major differences in the vital signs of the infants during the first 2 months of life (Table 3). The only difference was significantly higher heart rate in the SSRI group compared with the control group (P = .049, t31 = 2.039) at the age of 2 weeks.
A clear difference was seen in the perinatal clinical serotonergic symptoms between the study groups. There was a statistically significant, 4-fold difference in the serotonergic symptom score during the first 4 days of life between the SSRI group and the control group. The most prominent symptoms in the newborns included tremor, restlessness, and rigidity. One of the newborns in the SSRI (fluoxetine) group had myoclonus, which is considered a specific symptom of serotonergic overstimulation in adults but rarely seen in newborns.
Treatment with SSRIs induced a significant (69%) reduction of umbilical vein whole blood serotonin concentrations compared with the control group. Similarly, significantly lower concentrations of whole blood 5-HIAA (18%) and HVA (23%) were observed in the SSRI-exposed infants compared with the control group.
Treatment with SSRIs induced a significant (69%) reduction of umbilical vein whole blood serotonin concentrations compared with the control group (Table 4). Similarly, significantly lower concentrations of whole blood 5-HIAA (18%) and HVA (23%) were observed in the SSRI-exposed infants compared with the control group.
...we report increased risk for central nervous system serotonergic adverse effects during the first days of life in newborns of mothers taking the SSRIs citalopram or fluoxetine during the third trimester of pregnancy. However, these symptoms seem to subside quickly without any need for specific treatment. A timely relationship between declining drug concentrations and resolution of the adverse symptoms suggests that the mechanism behind the symptoms was central nervous system serotonergic overstimulation rather than an SSRI withdrawal syndrome.
There are a few significant differences between typical DMT usage patterns and SSRI treatment - namely, DMT is typically taken in acute doses/sessions, and not over the course of several days or weeks. Accordingly, given the mild reactions observed in these infants, as well as typical usage of the psychedelic, there most likely isn't anything significant to worry about.
However, as the title of the thread is "Is it safe to take DMT while breastfeeding," it's certainly worth mentioning that sustained use of any serotonergic psychedelic while pregnant is almost certainly hazardous - given the results observed in infants from enhanced serotonergic activity. This is speculation, but given the apparent lipophilicity of DMT, it's not unreasonable to anticipate reasonably conserved levels of DMT in breast milk, and may persist for a reasonably prolonged duration.
In sum, it's unlikely that acute doses of DMT will generate any significant repercussions during pregnancy - but studies do indeed show that enhanced serotonergic activity, derived from prolonged maternal exposure to drugs enhancing serotonergic activity, is deleterious to early development of infants. Accordingly, it's likely prudent - in effort to eliminate any probability of danger to the infant - to reserve potential DMT experiences for after a pregnancy has come to fruition. I suppose this is somewhat subjective, though.